. Author manuscript; available in PMC: 2023 Feb 1.

Published in final edited form as: Am J Gastroenterol. 2022 Feb 1;117(2):295–300. doi: 10.14309/ajg.0000000000001550

Table 2:

Details of the cohort who had Bristol Stool scale data collected

Cross-sectional outpatients (n=112)	Concordance between BSS and daily BMs			P value (ANOVA, χ² test)
Cross-sectional outpatients (n=112)	BSS<BMs (n=12)	Concordant (n=51)	BSS>BMs (n=49)	P value (ANOVA, χ² test)
Age (years)	63.3±9.7	62.2±9.3	62.2±9.3	0.96
Male sex	9 (75%)	48 (94%)	41 (84%)	0.11
MELD score	11.6±4.1	12.3±5.0	12.3±6.1	0.90
BSS	2.6±1.3	3.8±0.6	5.0±1.0	<0.0001
Daily BMs	2.0±1.2	2.5±0.8	2.2±1.1	0.09
Prior HE	7 (58%)	32 (63%)	39 (80%)	0.92
On rifaximin?	4 (33%)	25 (49%)	20 (41%)	0.53
On Lactulose?	5 (42%)	31 (61%)	29 (59%)	0.48
Lactulose dose (ml)	15.0±19.2	23.0±26.9	36.1±49.0	0.11
Other laxatives	4 (33%)	2 (4%)	8 (16%)	0.01
Fiber	1 (8%)	6 (12%)	7 (14%)	0.83
Opioid use	3 (25%)	4 (8%)	5 (10%)	0.30
Antibiotics	1 (8%)	2 (4%)	2 (4%)	0.35

BSS: Bristol Stool Scale, BM: bowel movements, HE: hepatic encephalopathy